Ligand id: 8362

Name: elagolix

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 13
Topological polar surface area 99.18
Molecular weight 631.21
XLogP 7.52
No. Lipinski's rules broken 2

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Elagolix is being assessed as a monotherapy in Phase III clinical trials as a potential treatment for endometriosis. Click here to link to ClinicalTrials.gov's list of Phase III elagolix trials.
Mechanism Of Action and Pharmacodynamic Effects
As a GnRHR antagonist, elegolix will act to suppress the pituitary-gonadal axis, leading to decreased levels of gonadal sex hormones. This is of clinical benefit in hormone-sensitive diseases such as endometriosis.